Recently, a phase 1 trial study of GD2-CAR-IL-15 NKT in refractory neuroblastoma showed that BTG1 is a key driver of hyporesponsiveness in exhausted NKT and T cells (45). The gene discussed is IL15; the disease is neuroblastoma.